Rocket Pharmaceuticals to Celebrate Rare Disease Day with Patient Artwork Event

February 19, 2020

The “I am RARE, hear me ROAR” event will feature patient artists hoping to raise awareness about their rare diseases.

Rocket Pharmaceuticals, a New York, NY-based clinical-stage pharmaceutical company focused on developing genetic therapies for rare childhood disorders, announced it will celebrate Rare Disease Day on Feb. 29, 2020 with an event co-hosted by the RTW Charitable Foundation titled “I am RARE, hear me ROAR.”

According to a Feb. 6, 2020 company press release, the event will highlight the Roaring ‘20s, a time period that introduced many innovative medicines that saved millions of lives, such as penicillin and insulin. The event will allow patients to raise awareness about their diseases through artwork while providing attendees the opportunity to interact with rare disease patients, caregivers, patient advocates, researchers, and physicians. Additionally, the Empire State Building will be lit with the official colors of the Rare Disease Day movement, pink, blue, purple, and green.

“At Rocket, our focus is first and foremost on the patients we are endeavoring to serve, and Rare Disease Day is the perfect time to not only bring that focus to the forefront of everyone’s mind, but to give patients the opportunity to tell their stories and give researchers and those working in biotech a better understanding of the incredible individuals within the rare disease community,” said Kinnari Patel, CEO and head of Development at Rocket, in the press release. “The theme of Rare Disease Day this year, ‘Rare is many, rare is strong and rare is proud!', brings the focus on increased equity for the rare disease community, and we welcome everyone interested to attend and learn more about how they can join this important movement. We believe that as the 1920s saw monumental strides in healthcare and medicine, the 2020s will usher in a new era of finding cures for rare genetic diseases, and we look forward to helping make an impact this decade.”

Source: Rocket Pharmaceuticals